A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520.
Daniel Oscar Persky
No relevant relationships to disclose
Steven H. Bernstein
No relevant relationships to disclose
Bryan H. Goldman
No relevant relationships to disclose
Lisa M. Rimsza
No relevant relationships to disclose
Richard I. Fisher
No relevant relationships to disclose
Thomas P. Miller
Research Funding - Spectrum Pharmaceuticals